window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 15, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

depression

  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Compass reports second positive Phase 3 trial of psilocybin therapy for treatment-resistant depression

    Compass Pathways has reported positive six-month results from its second [...]

    July 8, 2026
  • Digital & Data,Drug Discovery & Development,Opinion & Events

    Prenuvo research links alcohol and exercise to early brain and organ changes in asymptomatic adults

    Two new studies presented at the 2025 ISMRM Annual Meeting [...]

    May 5, 2026
  • Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Opinion & Events

    Rejoyn becomes first prescription-only app for depression in Great Britain with its mode of action

    Clinically validated digital therapeutic launches with UKCA mark and NHS [...]

    May 5, 2026
  • Drug Discovery & Development

    Elkedonia raises EUR 11.25 million to develop new treatment for depression and other neuropsychiatric disorders

    New approach targets Elk1 to restore neuroplasticity without sedation or [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • mRNA therapy shows potential for treating autoimmune diseases
    Categories: Drug Discovery & Development, Research & Development, Therapeutic Areas
  • Australian Phase 1 trial begins for CAR-T therapy targeting solid tumours
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development
  • Atsena selects clinical candidate for Stargardt disease gene therapy
    Categories: Advanced Therapies, Drug Discovery & Development, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top